Amylyx Pharmaceuticals Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Cambridge MA United States (2013)

Organization Overview

First Clinical Trial
2017
NCT03127514
First Marketed Drug
2022
sodium phenylbutyrate (buphenyl)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AMYLYX | Amylyx Pharmaceuticals | Amylyx Pharmaceuticals Inc.